Featured Article Cover Story Product Launch Partnership Research Updates Regulatory Updates Bond Vet and Small Door Veterinary Complete Merger Corporate transaction Bond Vet and Small Door Veterinary have completed their merger, creating one of the largest premium veterinary care networks ...
Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
Featured Article Cover Story Regulatory Updates Launch Product Launch PetMeds Receives New Acquisition Proposal Corporate transaction PetMed Express has received an unsolicited, non-binding proposal from SilverCape Investments to acquire all outstanding shares for $3.00 per share in cash. ...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Featured Article Cover Story Research & Innovation Financing & Partnerships Product Launches Mergers & Acquisitions Regulatory Updates At a Glance Merck Animal Health Expands Poultry Tech Portfolio Acquisition Merck Animal Health has agreed to acquire TARGAN, adding advanced po...
Quick Takeaways: Why It Matters? Merck Animal Health is doubling down on biodevices and automation in poultry by buying TARGAN, turning from a strategic investor into full owner of high-speed sexing and precision vaccination tech Source: Businesswire...
The European Medicines Agency (EMA) is continuing to accelerate innovation in animal healthcare, with its 2025 veterinary approvals reflecting strong momentum across poultry vaccines, companion animal therapeutics, livestock disease prevention, and aquaculture solutions. The latest wave of...
Quick Takeaways: Why It Matters? BiomEdit’s new patents effectively lock up its engineered Lactobacillus reuteri pvAb platform, giving it composition‑of‑matter and methods‑of‑use protection around BE‑101 and future in situ biologic payloads delivered vi...
Quick Takeaways: Why It Matters? The USDA’s positive safety verdict for Ecovaxxin MG significantly de‑risks US registration, validating ECO’s live‑strain platform and setting up a clear path toward a 2027 filing in a large Mycoplasma gallisepticum market.&nb...
